1-3 of 3
Marta Olesnyckyj, RN
Close
Sort by
Journal Articles

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Paul Richardson, MD, Sundar Jagannath, MD, Mohamad Hussein, MD, James Berenson, MD, Seema Singhal, MD, David Irwin, MD, Stephanie F. Williams, MD, William Bensinger, MD, Ashraf Z. Badros, MD, Robert Vescio, MD, Laurie Kenvin, BSN, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Herbert Faleck, DO, Jerome Zeldis, MD, Robert Knight, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2005) 106 (11): 1565.
https://doi.org/10.1182/blood.V106.11.1565.1565
Published: 2005
Journal Articles

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Meletios A. Dimopoulos, MD, Andrew Spencer, MBBS, Michael Attal, MD, PRD, Miles Prince, MD, Jean-Luc Harousseau, MD, Anna Dmoszynska, MD, PhD, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Jerome Zeldis, MD, Robert Knight, MD
Journal: Blood
Blood (2005) 106 (11): 6.
https://doi.org/10.1182/blood.V106.11.6.6
Published: 2005
Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 208.
https://doi.org/10.1182/blood.V104.11.208.208
Published: 2004